Cite
HARVARD Citation
Choudhury, A. et al. (2018). A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration‐resistant prostate cancer. Prostate. 78 (14), pp. 1053-1062. [Online].